MARKET

CORT

CORT

Corcept Therapeutics Inc
NASDAQ
23.00
-0.39
-1.67%
Closed 16:00 04/17 EDT
OPEN
23.52
PREV CLOSE
23.39
HIGH
23.54
LOW
22.76
VOLUME
957.82K
TURNOVER
0
52 WEEK HIGH
34.28
52 WEEK LOW
20.87
MARKET CAP
2.39B
P/E (TTM)
24.21
1D
5D
1M
3M
1Y
5Y
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
NASDAQ · 1d ago
New Strong Buy Stocks for April 17th
NASDAQ · 1d ago
Corcept (CORT) Completes Enrollment in Phase II ALS Study
NASDAQ · 2d ago
Weekly Report: what happened at CORT last week (0408-0412)?
Weekly Report · 3d ago
CORCEPT COMPLETES ENROLLMENT IN PHASE 2 DAZALS TRIAL IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Reuters · 3d ago
Upcoming Deadline to Share in Corcept Therapeutics Incorporated (CORT) Class Action Settlement
TipRanks · 6d ago
ClearBridge Small Cap Strategy Q1 2024 Portfolio Manager Commentary
ClearBridge Small Cap Strategy underperformed the benchmark Russell 2000 Index in the first quarter by 177 bps. The two largest-capitalization stocks in the index - Super Micro Computer and MicroStrategy - contributed to the index's performance. Super Micro is now the largest position ever in the Russell 2000 index.
Seeking Alpha · 04/10 14:40
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
NASDAQ · 04/09 15:09
More
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Webull offers Corcept Therapeutics Incorporated stock information, including NASDAQ: CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CORT stock methods without spending real money on the virtual paper trading platform.